Cerus Corporation presented multiple abstracts and hosted a workshop at the 2024 Association for the Advancement of Blood & Biotherapies (AABB) Annual Meeting in Houston, Texas, focusing on the INTERCEPT Blood System and its clinical applications. The presentations covered a range of topics, from the efficacy of pathogen-reduced red blood cells in cardiac surgery to the logistical benefits of INTERCEPT Fibrinogen Complex.
ReCePI Trial and Acute Kidney Injury
E. Snyder presented findings from the Phase 3 ReCePI clinical trial, evaluating the impact of amustaline/glutathione pathogen-reduced red cells on acute kidney injury in cardiac surgery patients. The study aimed to assess whether pathogen reduction could improve outcomes in this vulnerable population. Further analysis by P. Norris explored HLA alloimmunization in the ReCePI trial, while R. Benjamin discussed treatment-emergent antibodies to amustaline/glutathione pathogen-reduced red blood cells.
INTERCEPT Fibrinogen Complex Efficiency
D. Chen presented data on the laboratory efficiency of INTERCEPT Fibrinogen Complex compared to traditional cryoprecipitate, utilizing Sankey diagrams to quantify the differences. The analysis highlighted potential improvements in workflow and resource utilization with the INTERCEPT product. M. Cushing presented on the TOPCLOT Phase IV trial of pathogen-reduced cryoprecipitate versus conventional cryoprecipitated AHF to lower operative transfusions in cardiac surgery.
Implementation and Impact of Pathogen-Reduced Cryoprecipitate
Several poster presentations detailed the implementation and impact of pathogen-reduced cryoprecipitate in various clinical settings. One study focused on accelerating treatment delivery and reducing waste with the implementation of pathogen-reduced cryoprecipitated fibrinogen complex. Another analysis covered wastage and cost for INTERCEPT Fibrinogen Complex. Additional research explored anesthesiologist and transfusion service staff preferences between pathogen-reduced cryoprecipitated fibrinogen complex and conventional cryoprecipitated AHF, as well as the impact of pooled pathogen-reduced cryoprecipitate on maternal and pediatric outcomes in comparison to conventional cryoprecipitate. Furthermore, the implementation of INTERCEPT Fibrinogen Complex (IFC) for postpartum hemorrhage was evaluated, alongside an assessment of the impact of pathogen-reduced cryoprecipitate in a large academic medical center.
Other Research
Additional posters covered the evaluation of pathogen reduction efficacy in platelet concentrates, the development of a next-generation illuminator for photochemical inactivation of pathogens in platelet concentrates, and the evaluation of INTERCEPT RBC pathogen reduction in combination with irradiation.
Industry Workshop
Cerus hosted an industry workshop titled "Pathogen Reduced Blood Components – Current Experiences and Future Developments with the INTERCEPT® Blood System," featuring J. Squires, C. Ingold, and E. Snyder as speakers. The workshop provided insights into the current state and future directions of pathogen reduction in blood components.
